These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34241782)

  • 1. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies.
    Kow CS; Hasan SS
    Inflammopharmacology; 2021 Aug; 29(4):1075-1090. PubMed ID: 34241782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis.
    Kow CSC; Ramachandram DS; Hasan SS
    Inflammopharmacology; 2022 Feb; 30(1):149-157. PubMed ID: 35099680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework.
    Wang X; Haeussler K; Spellman A; Phillips LE; Ramiller A; Bausch-Jurken MT; Sharma P; Krivelyova A; Vats S; Van de Velde N
    Front Immunol; 2023; 14():1204831. PubMed ID: 37771594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of mRNA-1273 vaccine against COVID-19 caused by Delta variant: A systematic review and meta-analysis.
    Kow CS; Ramachandram DS; Hasan SS
    J Med Virol; 2022 May; 94(5):2269-2274. PubMed ID: 34978339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
    Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
    JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
    Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
    BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
    Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM
    J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data.
    Chodick G; Tene L; Rotem RS; Patalon T; Gazit S; Ben-Tov A; Weil C; Goldshtein I; Twig G; Cohen D; Muhsen K
    Clin Infect Dis; 2022 Feb; 74(3):472-478. PubMed ID: 33999127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
    Mues KE; Kirk B; Patel DA; Gelman A; Chavers LS; Talarico CA; Esposito DB; Martin D; Mansi J; Chen X; Gatto NM; Van de Velde N
    Vaccine; 2022 Nov; 40(47):6730-6739. PubMed ID: 36163093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
    Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
    BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
    Chung H; He S; Nasreen S; Sundaram ME; Buchan SA; Wilson SE; Chen B; Calzavara A; Fell DB; Austin PC; Wilson K; Schwartz KL; Brown KA; Gubbay JB; Basta NE; Mahmud SM; Righolt CH; Svenson LW; MacDonald SE; Janjua NZ; Tadrous M; Kwong JC;
    BMJ; 2021 Aug; 374():n1943. PubMed ID: 34417165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis.
    Rahmani K; Shavaleh R; Forouhi M; Disfani HF; Kamandi M; Oskooi RK; Foogerdi M; Soltani M; Rahchamani M; Mohaddespour M; Dianatinasab M
    Front Public Health; 2022; 10():873596. PubMed ID: 36091533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.
    Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y
    BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.
    Thompson MG; Burgess JL; Naleway AL; Tyner HL; Yoon SK; Meece J; Olsho LEW; Caban-Martinez AJ; Fowlkes A; Lutrick K; Kuntz JL; Dunnigan K; Odean MJ; Hegmann KT; Stefanski E; Edwards LJ; Schaefer-Solle N; Grant L; Ellingson K; Groom HC; Zunie T; Thiese MS; Ivacic L; Wesley MG; Lamberte JM; Sun X; Smith ME; Phillips AL; Groover KD; Yoo YM; Gerald J; Brown RT; Herring MK; Joseph G; Beitel S; Morrill TC; Mak J; Rivers P; Harris KM; Hunt DR; Arvay ML; Kutty P; Fry AM; Gaglani M
    MMWR Morb Mortal Wkly Rep; 2021 Apr; 70(13):495-500. PubMed ID: 33793460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
    Hippisley-Cox J; Patone M; Mei XW; Saatci D; Dixon S; Khunti K; Zaccardi F; Watkinson P; Shankar-Hari M; Doidge J; Harrison DA; Griffin SJ; Sheikh A; Coupland CAC
    BMJ; 2021 Aug; 374():n1931. PubMed ID: 34446426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5-17 years in the United States: a cohort study.
    Ogilvie RP; Layton JB; Lloyd PC; Jiao Y; Djibo DA; Wong HL; Gruber JF; Parambi R; Deng J; Miller M; Song J; Weatherby LB; Peetluk L; Lo AC; Matuska K; Wernecke M; Bui CL; Clarke TC; Cho S; Bell EJ; Yang G; Amend KL; Forshee RA; Anderson SA; McMahill-Walraven CN; Chillarige Y; Anthony MS; Seeger JD; Shoaibi A
    BMC Pediatr; 2024 Apr; 24(1):276. PubMed ID: 38671379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.